16 results about "Mediator" patented technology

This application relates to a biosensing electrode with sarcosine oxidase-directed modification, its preparation method, and its application in the field of biosensing technology. The biosensing electrode includes: a metal electrode, and a DNA-enzyme composite nanostructure connected to the metal electrode; the DNA-enzyme composite nanostructure includes a DNA electron transport module and an enzyme catalysis module; the DNA electron transport module includes a DNA sheet structure and a mediator embedded in the DNA sheet structure; the enzyme catalysis module includes a sarcosine oxidase substrate complex, which is connected to the DNA sheet structure; the sarcosine oxidase substrate complex, the mediator-containing DNA sheet structure, and the metal electrode are spatially ordered in the sequence of sarcosine oxidase substrate complex – mediator-containing DNA sheet structure – metal electrode. This biosensing electrode, under the condition of introducing a mediator, can improve the electron transport rate, thus exhibiting a good signal response during sarcosine testing.

A method for determining the presence of a molecule coupled to the cytoplasmic side of a cellular membrane is disclosed. The method is implemented in a microfluidic setting and is particularly suitable for determining the presence and / or the activity of a G protein or an arrestin protein in a cell.

This invention belongs to the field of medicine, specifically disclosing a drug-loaded biomimetic nanodecoy based on genetic engineering, its preparation method, and its application. The drug-loaded biomimetic nanodecoy of this invention comprises CCR2-overexpressing nanovesicles, and the hydrophobic regions of the nanovesicles are loaded with curcumin. This invention also provides a method for preparing the drug-loaded biomimetic nanodecoy based on genetic engineering and its application. The overexpressed CCR2 is used to adsorb excess CCL2 to inhibit the binding of macrophages to CCL2, preventing macrophage chemotaxis and subsequent TGF-β production. This inhibits the activation of hepatic stellate cells by removing pro-fibrotic mediators upstream; simultaneously, curcumin is released to block the downstream TGF-β / Smad signaling pathway, thereby inhibiting the activation of hepatic stellate cells.

The present invention provides complexes of a specialized pro-resolving mediator (SPM), or a salt, ester, or amide thereof, and a cyclodextrin (CD), wherein the SPM is a hydroxylated, polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length, with 4, 5 or 6 conjugated double bonds arranged in diene, triene, or tetraene systems or combinations thereof, and related compositions and methods.

This invention relates to the field of biodetection technology, specifically to a multimodal miRNA detection array based on Mn-CeO2@CDs nanozymes and Cas12a sensing, its preparation method, and its applications. The recognition and signal amplification probe composition based on Mn-CeO2@CDs nanozymes and Cas12a includes: a solid substrate, the DNA Y-shaped structure described in the first aspect, the composite nanozyme, and a CRISPR / Cas12a system. This invention combines DNA nanotechnology, Cas12a enzyme digestion technology, and nanozymes as signal output mediators, achieving highly specific and sensitive multimodal detection of myocarditis biomarkers (miRNAs) in fluorescence, UV-visualization, and electrochemical modes.

The present invention provides peptides that specifically bind to maternal autoantibodies that are generated in the mother or potential mother against one or more endogenous polypeptide antigens selected from lactate dehydrogenase A (LDH A), lactate dehydrogenase B (LDH B), stress-induced phosphoprotein 1 (STIP1), guanine deaminase (GDA), Y Box Binding Protein 1 (YBX1), collapsin response mediator protein 1 (CRMP1), and collapsin response mediator protein 2 (CRMP2). The peptides described herein are useful for determining a risk of an offspring for developing an autism spectrum disorder (ASD) by detecting the presence of maternal autoantibodies in a biological sample of the mother or potential mother. The peptides or mimotopes thereof can also be administered to the mother or potential mother to block the binding between maternal autoantibodies and their antigens, thereby neutralizing the maternal autoantibodies.

This invention relates to the fields of regenerative medicine and neuromodulation technology, specifically disclosing the application of mediators that inhibit the activity of the auditory cortex in the preparation of drugs or intervention devices for promoting cartilage regeneration, repairing cartilage damage, and delaying or treating osteoarthritis. This invention promotes cartilage damage repair and osteoarthritis treatment by modulating the auditory cortex of the auditory center, providing two technical means: a chemogenetic method involving targeted injection of a viral vector carrying an artificial inhibitory receptor into the auditory cortex followed by administration of a DREADD agonist; and a sound stimulation method involving outputting sound stimulation to the individual at a level 5 dB higher than the ambient background noise. Animal experiments have confirmed that both methods can upregulate the expression of cartilage synthesis markers Col2, Acan, and PRG4, downregulate the expression of degradation markers Col1 and Mmp13, improve histological scores, and alleviate pain. This invention also provides an intervention device, including a sound insulation unit, a sound acquisition unit, a control unit, and a sound output unit. This device has the advantages of being non-invasive, easy to operate, and highly safe, providing an innovative strategy for cartilage regeneration and osteoarthritis treatment.

The application relates to an ordered sensing interface based on a DNA-enzyme composite nanostructure and a construction method and application thereof. The ordered sensing interface comprises an electrode and a DNA-enzyme composite nanostructure connected to the electrode; the DNA-enzyme composite nanostructure comprises a DNA electronic transmission module and an enzyme catalysis module; the DNA electronic transmission module comprises a mediator-containing DNA sheet structure; the enzyme catalysis module comprises an enzyme substrate complex connected to the DNA sheet structure; and the enzyme substrate complex, the mediator-containing DNA sheet structure and the electrode are sequentially and orderly distributed in space in the order of enzyme substrate complex-mediator-containing DNA sheet structure-electrode. Through the design of the enzyme substrate complex and the DNA sheet structure, the enzyme is orderly fixed, the influence of spatial interference and non-specific interaction on electron transmission is reduced, and the embedded mediator can improve the electrode interface electron transmission rate.

Detection reagents, multi-analyte test elements, test systems, and multi-analyte measuring methods are provided. In particular, multi-analyte test elements have (1) a first working electrode and first counter electrode pair covered with a first analyte-specific reagent that includes an enzyme, a coenzyme and a first mediator and have (2) a second working electrode covered with a second analyte-specific reagent that includes an enzyme, a coenzyme and a second mediator, where the second mediator is different than the first mediator. The single counter electrode can be used as the counter electrode for both the first and second analyte measurements at their respective working electrodes. Moreover, the mediator concentrations, measurement ranges, and applied potential differences are not the same for each analyte-specific measurement.

This invention discloses a method for degrading municipal solid waste sludge based on interfacial cell disruption and enzyme-mediator co-catalysis, belonging to the field of solid waste treatment and resource utilization technology. Addressing the problems of dense extracellular polymer structures, slow hydrolysis rates, high energy consumption of traditional pretreatment methods, easy secondary pollution, and highly overlapping technical routes in municipal solid waste sludge, this invention employs electro-induced asymmetric plasma interfacial discharge to achieve selective cell disruption of sludge flocs under low-temperature, chemical-oxidant-free, and acid- and alkali-free conditions. Immobilized enzyme-biomimetic redox mediator co-loaded particles simultaneously complete the directional depolymerization of macromolecular organic matter and the construction of electron transport pathways. Furthermore, a pulsed micro-aerobic-anaerobic alternating mode triggered by redox potential in real time intelligently matches the activity of hydrolytic bacteria and methanogenic bacteria, achieving efficient sludge degradation. This invention operates under mild conditions throughout, without secondary pollution, and can significantly improve the soluble organic matter dissolution rate, volatile solids removal rate, and methane yield of sludge, while greatly shortening the hydraulic retention time.

This invention provides the application of JAK1 inhibitors in the preparation of drugs for treating adverse reactions related to immune checkpoint blockade. The CD8 inhibitor of this invention... + CTLs in T cells irAE Subgroups are key mediators of adverse reactions associated with multi-organ immunotherapy, specifically overexpressing JAK1 and activating the JAK-STAT signaling pathway, while anti-tumor CD8... + T cell subset 1 (CTL1) shows low JAK1 expression. Inhibitors specifically targeting JAK1 can block CTL expression. irAE‑Ⅱ Inhibiting the JAK-STAT pathway in subpopulations alleviates adverse reactions in multiple organs, including the heart and lungs, without affecting the anti-tumor CD8 inhibitors. + The anti-tumor function of T cell subsets can also enhance the efficacy of immune checkpoint inhibitors.

The application discloses a sorbitol dehydrogenase mutant capable of efficiently degrading vomitoxin without relying on exogenous mediators, and belongs to the field of agricultural biotechnology. The mutant is obtained by rational design and directional evolution of wild-type sorbitol dehydrogenase (SDH), and contains three mutant sites of F103A, S454E and T492E, and the amino acid sequence and the nucleotide sequence are respectively SEQ ID NO. 1 and SEQ ID NO. 2. F103A / S454E / T492E The mutant SDH can efficiently degrade vomitoxin (DON) without relying on electron transfer replacement phenazine methosulfate (PMS), and the degradation efficiency can reach 82% in the absence of PMS. The application can be applied to the preparation of vomitoxin detoxification enzyme, and has a good application prospect in the biological detoxification of DON in feed, grain and food.

The present invention provides engineered platelets having a chimeric platelet receptor (CPR) with desired target specificity. Furthermore, the engineered platelets may contain cargo that can be released upon platelet activation. In addition, the platelets can be generated in vitro from megakaryocytes engineered to produce non-thrombotic platelets. [Solution] To provide an engineered megakaryocyte or precursor capable of reducing thrombogenic ability and / or producing platelets with reduced thrombogenic ability, comprising the disruption or deletion of at least one gene encoding a protein involved in the recognition of a primary stimulus for thrombosis, one gene encoding a protein involved in the recognition of a secondary mediator for thrombosis, and one gene encoding a protein involved in the release of a secondary mediator for thrombosis.

This application belongs to the field of multiplex detection of nucleic acid molecules, and relates to a probe set, a kit, and a method for detecting two or more target nucleic acids. The probe set includes at least one linear fluorescent probe and at least two mediator probes. Each mediator probe independently contains a mediator sequence and a target probe sequence from the 5' to 3' direction. The linear fluorescent probe contains a label sequence and a positioning sequence from the 5' to 3' direction. When multiple mediator sequences are simultaneously paired on the linear fluorescent probe, there is at least 2 nt of overlapping nucleotides between each pair of mediator sequences; or, if the downstream mediator sequence and the upstream mediator sequence have less than 2 nt of non-overlapping nucleotides, the 5' end of the upstream mediator sequence is modified with a nuclease-resistant modification. The technical solution provided by this application can prevent the mediator sequence of the mediator probe from being cleaved by enzymes with 5' nuclease activity, resulting in a relatively flat baseline for the melting analysis curve, which is beneficial for the identification of the melting peak and the reading of the Tm value.